Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites

Tropical Medicine and International Health

Volumn 15, Issue 11, 2010, Pages 1357-1363

  Ruan, Yuhua ^a   Xing, Hui ^a   Wang, Xia ^a   Tang, Heng ^b   Wang, Zhe ^c   Liu, Hongwei ^c   Su, Bin ^d   Wu, Jianjun ^d   Li, Hanping ^e   Liao, Lingjie ^a   Li, Jingyun ^e   Wu, Julia Wei ^f   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c HENAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Anhui Provincial Center for Disease Control and Prevention   (China)

^e BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretroviral therapy; China; HIV drug resistance; HIV RNA

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIMICROBIAL ACTIVITY; COHORT ANALYSIS; DECISION MAKING; DISEASE PREVALENCE; DISEASE TREATMENT; DRUG RESISTANCE; ENZYME ACTIVITY; IMMUNE RESPONSE; INHIBITOR; MORTALITY; RNA; TELEPHONE NETWORK; VIRUS; WORLD HEALTH ORGANIZATION;

ADULT; AGRICULTURAL WORKER; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINESE; COUNSELING; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; TELECONSULTATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; EPIDEMIOLOGIC METHODS; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79251491368     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2010.02621.x     Document Type: Article

References (23)

1. Borrell C, Rodriguez-Sanz M, Pasarin MI et al. (2006) AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System? European Journal of Public Health 16, 601-608.
2. Carr A, Chuah J, Hudson J et al. (2000) A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 14, 1171-1180.
3. Coetzee D, Hildebrand K, Boulle A et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18, 887-895.
4. Hosseinipour MC, Van Oosterhout JJ, Weigel R et al. (2009) The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23, 1127-1134.
5. Johannessen A, Naman E, Kivuyo SL et al. (2009) Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infectious Diseases 9, 108.
6. Jordan MR, Bennett DE, Bertagnolio S et al. (2008) World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Therapy 13(S2), 15-23.
7. Koenig SP, Léandre F & Farmer PE (2004) Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS 18, S21-S25.
8. Koyalta D, Charpentier C, Beassamda J et al. (2009) High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clinical Infectious Diseases 49, 155-159.
9. Laurent C, Diakhate N, Gueye NF et al. (2002) The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 16, 1363-1370.
10. Liao L, Xing H, Shang H et al. (2010) The Prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. Journal of Acquired Immune Deficiency Syndromes 53, S10-S14.
11. Lima VD, Hogg RS, Harrigan PR et al. (2007) Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21, 685-692.
12. Luo M, Liu H, Zhuang K et al. (2009) Prevalence of drug-resistant HIV-1 in rural areas of Hubei province in the People's Republic of China. Journal of Acquired Immune Deficiency Syndromes 50, 1-8.
13. MacArthur RD, Novak RM, Peng G et al. (2006) A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 368, 2125-2135.
14. Shafer RW (2006) Rationale and uses of a public HIV drug-resistance database. The Journal of Infectious Diseases 194(Suppl. 1), S51-S58.
15. Shafer RW, Rhee SY, Pillay D et al. (2007) HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21, 215-223.
16. Smith D, Berrey MM, Robertson M et al. (2000) Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. Journal of Infectious Diseases 182, 950-954.
17. Smith CJ, Sabin CA, Lampe FC et al. (2003) The potential for CD4 cell increases in HIV positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 17, 963-969.
18. UNAIDS (2008) 2008 Report on the Global AIDS Epidemic UNAIDS, Geneva, Switzerland.
19. Weidle PJ, Malamba S, Mwebaze R et al. (2002) Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 360, 34-40.
20. Zhang F, Dou Z, Yu L et al. (2008a) The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clinical Infectious Diseases 47, 825-833.
21. Zhang M, Han XX, Cui WG et al. (2008b) The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation. Japanese Journal of Infectious Diseases 61, 361-365.
22. Zhang F, Dou Z, Ma Y et al. (2009) Five-year outcomes of the China National Free Antiretroviral Treatment Program. Annals of Internal Medicine 151, 241-251.
23. Zhong P, Pan Q, Ning Z et al. (2007) Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses 23, 847-856.